- Home
- INZY vs IMRX Comparison
INZY vs IMRX Comparison
Compare INZY & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- IMRX
- Stock Information
- Founded
- INZY 2015
- IMRX 2008
- Country
- INZY United States
- IMRX United States
- Employees
- INZY N/A
- IMRX N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- INZY Health Care
- IMRX Health Care
- Exchange
- INZY Nasdaq
- IMRX Nasdaq
- Market Cap
- INZY 64.9M
- IMRX 62.7M
- IPO Year
- INZY 2020
- IMRX 2021
- Fundamental
- Price
- INZY $0.92
- IMRX $1.27
- Analyst Decision
- INZY Strong Buy
- IMRX Strong Buy
- Analyst Count
- INZY 9
- IMRX 2
- Target Price
- INZY $17.22
- IMRX $12.50
- AVG Volume (30 Days)
- INZY 453.8K
- IMRX 170.4K
- Earning Date
- INZY 05-06-2025
- IMRX 05-06-2025
- Dividend Yield
- INZY N/A
- IMRX N/A
- EPS Growth
- INZY N/A
- IMRX N/A
- EPS
- INZY N/A
- IMRX N/A
- Revenue
- INZY N/A
- IMRX N/A
- Revenue This Year
- INZY N/A
- IMRX N/A
- Revenue Next Year
- INZY N/A
- IMRX N/A
- P/E Ratio
- INZY N/A
- IMRX N/A
- Revenue Growth
- INZY N/A
- IMRX N/A
- 52 Week Low
- INZY $0.72
- IMRX $1.00
- 52 Week High
- INZY $6.24
- IMRX $3.83
- Technical
- Relative Strength Index (RSI)
- INZY 44.29
- IMRX 34.48
- Support Level
- INZY $0.83
- IMRX $1.23
- Resistance Level
- INZY $1.08
- IMRX $1.38
- Average True Range (ATR)
- INZY 0.11
- IMRX 0.11
- MACD
- INZY 0.02
- IMRX -0.01
- Stochastic Oscillator
- INZY 55.43
- IMRX 26.42
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.